Michelangelo Fiorentino

Beta-Catenin Alterations in Postchemotherapy Yolk Sac Tumor, Postpubertal-Type With Enteroblastic Features.

Surucu A, de Biase D, Ricci C, di Sciascio L, Collins K, Idrees MT, Ebare K, Fiorentino M, Bridge JA, Ulbright TM, Acosta AM.

Mod Pathol. 2024 Jul. 37(7):100513. PMID: 38763421

ß-Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis.

Kitagawa Y, De Biase D, Ricci C, Cornejo KM, Fiorentino M, Collins K, Idrees MT, Colecchia M, Ulbright TM, Acosta AM, Kitagawa Y, De Biase D, Ricci C, Cornejo KM, Fiorentino M, Collins K, Idrees MT, Colecchia M, Ulbright TM, Acosta AM, Kitagawa Y, De Biase D, Ricci C, Cornejo KM, Fiorentino M, Collins K, Idrees MT, Colecchia M, Ulbright TM, Acosta AM.

Histopathology. 2024 Jul. 85(1):75-80. PMID: 38530207

Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.

Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Ricci C, Fiorentino M, Tallini G, De Biase D, Massari F.

Pathol Res Pract. 2024 Feb. 254:155142. PMID: 38277752

Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation.

Ricci C, Ambrosi F, Grillini A, Massari F, Fiorentino M, Colecchia M, Ulbright TM, Acosta AM.

Virchows Arch. 2024 Apr. 484(4):709-713. PMID: 38141134

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.

Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase D, Massari F.

Pathol Res Pract. 2024 Jan. 253:155008. PMID: 38103361

Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.

Ricci C, Ambrosi F, Franceschini T, Giunchi F, Grillini A, Franchini E, Grillini M, Schiavina R, Massari F, Mollica V, Tateo V, Bianchi FM, Bianchi L, Droghetti M, Maloberti T, Tallini G, Colecchia M, Acosta AM, Lobo J, Trpkov K, Fiorentino M, de Biase D.

Virchows Arch. 2023 Nov. 483(5):687-698. PMID: 37845471

Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort.

Destefanis N, Fiano V, Milani L, Vasapolli P, Fiorentino M, Giunchi F, Lianas L, Del Rio M, Frexia F, Pireddu L, Molinaro L, Cassoni P, Papotti MG, Gontero P, Calleris G, Oderda M, Ricardi U, Iorio GC, Fariselli P, Isaevska E, Akre O, Zelic R, Pettersson A, Zugna D, Richiardi L.

Front Oncol. 2023. 13:1242639. PMID: 37869094

Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals.

Iyer HS, Vaselkiv JB, Stopsack KH, Roscoe C, DeVille NV, Zhang Y, Penney KL, Balk SP, Fiorentino M, Hart JE, James P, De Vivo I, Mucci LA, Laden F, Rebbeck TR.

Am J Epidemiol. 2023 09 01. 192(9):1485-1498. PMID: 37139568

An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre Experience.

Gaudiano C, Mottola M, Bianchi L, Corcioni B, Braccischi L, Tomassoni MT, Cattabriga A, Cocozza MA, Giunchi F, Schiavina R, Fanti S, Fiorentino M, Brunocilla E, Mosconi C, Bevilacqua A.

Cancers (Basel). 2023 Jun 30. 15(13). PMID: 37444548

FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type.

Ricci C, Ambrosi F, Franceschini T, Giunchi F, Di Filippo G, Franchini E, Massari F, Mollica V, Tateo V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M.

Histopathology. 2023 Sep. 83(3):465-476. PMID: 37317674